Recombinant Anti-CXCL1/GRO alpha antibody [EPR19892] (ab206411)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR19892] to CXCL1/GRO alpha
- Suitable for: WB
- Knockout validated
- Reacts with: Human, Recombinant fragment
Related conjugates and formulations
Overview
-
Product name
Anti-CXCL1/GRO alpha antibody [EPR19892]
See all CXCL1/GRO alpha primary antibodies -
Description
Rabbit monoclonal [EPR19892] to CXCL1/GRO alpha -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Human, Recombinant fragment -
Immunogen
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Human CXCL1/GRO alpha active protein; human GRO beta fragment recombinant protein; human GRO gamma fragment recombinant protein; human fetal lung lysate.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR19892 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab206411 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/100. Detects a band of approximately 11 kDa (predicted molecular weight: 11 kDa).
|
Notes |
---|
WB
1/100. Detects a band of approximately 11 kDa (predicted molecular weight: 11 kDa). |
Target
-
Function
Has chemotactic activity for neutrophils. May play a role in inflammation and exerts its effects on endothelial cells in an autocrine fashion. In vitro, the processed forms GRO-alpha(4-73), GRO-alpha(5-73) and GRO-alpha(6-73) show a 30-fold higher chemotactic activity. -
Sequence similarities
Belongs to the intercrine alpha (chemokine CxC) family. -
Post-translational
modificationsN-terminal processed forms GRO-alpha(4-73), GRO-alpha(5-73) and GRO-alpha(6-73) are produced by proteolytic cleavage after secretion from peripheral blood monocytes. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 2919 Human
- Omim: 155730 Human
- SwissProt: P09341 Human
- Unigene: 708652 Human
- Unigene: 789 Human
-
Alternative names
- C-X-C motif chemokine 1 antibody
- Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) antibody
- chemokine (C-X-C motif) ligand 1 antibody
see all
Images
-
All lanes : Anti-CXCL1/GRO alpha antibody [EPR19892] (ab206411) at 1/100 dilution
Lane 1 : Wild-type HeLa Treated TNF alpha (5 ng/mL, 6 h) + BFA (5 ug/mL, 6 h) cell lysate
Lane 2 : CXCL1 knockout HeLa Treated TNF alpha (5 ng/mL, 6 h) + BFA (5 ug/mL, 6 h) cell lysate
Lysates/proteins at 20 µg per lane.
Performed under reducing conditions.
Predicted band size: 11 kDa
Observed band size: 8 kDa why is the actual band size different from the predicted?False colour image of Western blot: Anti-CXCL1/GRO alpha antibody [EPR19892] staining at 1/100 dilution, shown in black; Mouse anti-Alpha Tubulin [DM1A] (ab7291) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab206411 was shown to bind specifically to CXCL1/GRO alpha. A band was observed at 8 kDa in treated wild-type HeLa cell lysates with no signal observed at this size in CXCL1 knockout cell line ab261774 (knockout cell lysate ab257079). To generate this image, wild-type and CXCL1 knockout HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times before development with Optiblot (ECL reagent ab133456) and imaged with 20 minutes exposure time. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and HRP conjugated Goat anti-Mouse (H+L) at 1/20000 dilution.
-
All lanes : Anti-CXCL1/GRO alpha antibody [EPR19892] (ab206411) at 1/1000 dilution
Lane 1 : Human CXCL1/GRO alpha active protein
Lane 2 : Human GRO beta fragment recombinant protein
Lane 3 : Human GRO gamma fragment recombinant protein
Lysates/proteins at 0.01 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 11 kDa
Observed band size: 10,36 kDa why is the actual band size different from the predicted?
Exposure time: 3 minutesBlocking/Dilution buffer: 5% NFDM/TBST.
Human GRO beta fragment recombinant protein contain aa35-107 with a GST-Tag. Human GRO gamma fragment recombinant protein contain aa35-107 with a His-Tag®. These two protein were made in house.
-
Anti-CXCL1/GRO alpha antibody [EPR19892] (ab206411) at 1/100 dilution + Human fetal lung lysate at 10 µg
Secondary
Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 11 kDa
Observed band size: 11 kDa
Exposure time: 3 minutesBlocking/Dilution buffer: 5% NFDM/TBST.
Datasheets and documents
-
Datasheet download
Certificate of Compliance
References (1)
ab206411 has been referenced in 1 publication.
- Wang F et al. Bioinformatics, Molecular Docking and Experiments In Vitro Analyze the Prognostic Value of CXC Chemokines in Breast Cancer. Front Oncol 11:665080 (2021). PubMed: 34123826